|  |
June 2003 Stock Report
| Company |
6/27/2003 Close |
% 52wk High |
% change from 6/28/2002 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value / Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| GENOME THERAPEUTICS CORP |
$2.69 |
67% |
16% |
$64 |
$40 |
$23 |
$15 |
152 |
$0.2 |
-$34.8 |
1.2 |
2.3 |
| HUMAN GENOME SCIENCES |
$12.57 |
67% |
-6% |
$1,621 |
$1,199 |
$422 |
$503 |
1086 |
$0.4 |
-$165.3 |
7.3 |
0.9 |
| INCYTE CORP |
$4.73 |
63% |
-35% |
$339 |
$376 |
-$37 |
$172 |
585 |
-$0.1 |
-$223.1 |
1.7 |
0.5 |
| MILLENNIUM PHARMACEUTICALS |
$15.64 |
85% |
29% |
$4,647 |
$1,652 |
$2,995 |
$83 |
2079 |
$1.4 |
-$551.4 |
3.0 |
1.0 |
| MYRIAD GENETICS |
$14.22 |
54% |
-30% |
$384 |
$93 |
$291 |
$0 |
491 |
$0.6 |
-$22.1 |
4.2 |
1.5 |
| 1st Generation Genomics Average |
|
67% |
-5% |
$1,411 |
$672 |
$739 |
$155 |
|
$0.5 |
-$199.4 |
3.5 |
1.2 |
| 1st Generation Genomics Median |
|
67% |
5% |
$362 |
$235 |
$157 |
$49 |
|
$0.5 |
-$100.1 |
2.3 |
1.0 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
6/27/2003 Close |
% 52wk High |
% change from 6/28/2002 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value / Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| ACLARA BIOSCIENCES |
$4.09 |
91% |
138% |
$145 |
$84 |
$61 |
$0 |
95 |
$0.6 |
-$24.9 |
3.4 |
0.6 |
| AFFYMETRIX |
$19.41 |
65% |
-19% |
$1,141 |
$429 |
$713 |
$369 |
877 |
$0.8 |
-$50.9 |
8.4 |
3.2 |
| CALIPER TECHNOLOGIES |
$4.24 |
51% |
-49% |
$105 |
$144 |
-$39 |
$1 |
251 |
-$0.2 |
-$39.9 |
3.6 |
0.4 |
| CEPHEID |
$4.45 |
68% |
-20% |
$144 |
$16 |
$129 |
$0 |
148 |
$0.9 |
-$18.8 |
0.8 |
1.6 |
| CIPHERGEN BIOSYSTEMS |
$9.93 |
94% |
181% |
$272 |
$36 |
$235 |
$0 |
323 |
$0.7 |
-$36.8 |
1.0 |
1.6 |
| COMBIMATRIX |
$2.46 |
49% |
na |
$57 |
na |
na |
na |
14 |
na |
-$26.7 |
na |
na |
| COMPUGEN |
$4.90 |
78% |
123% |
$128 |
na |
na |
na |
176 |
na |
na |
na |
na |
| ILLUMINA |
$2.87 |
42% |
-57% |
$94 |
$60 |
$33 |
$25 |
233 |
$0.1 |
-$35.8 |
1.7 |
1.5 |
| NANOGEN |
$2.50 |
50% |
-29% |
$55 |
$37 |
$18 |
$0 |
195 |
$0.1 |
-$42.7 |
0.9 |
0.3 |
| ORCHID BIOSCIENCES |
$1.26 |
63% |
-5% |
$70 |
na |
na |
$2 |
492 |
na |
-$17.1 |
na |
0.2 |
| SEQUENOM |
$2.74 |
78% |
-22% |
$108 |
$84 |
$24 |
$10 |
216 |
$0.1 |
-$34.2 |
2.5 |
0.2 |
| TRANSGENOMIC |
$2.04 |
44% |
-19% |
$48 |
$6 |
$42 |
$1 |
326 |
$0.1 |
-$14.4 |
0.4 |
0.4 |
| Genomic Supply Average |
|
64% |
20% |
$197 |
$100 |
$135 |
$41 |
|
$0.4 |
-$31.1 |
2.5 |
1.0 |
| Genomic Supply Median |
|
65% |
-19% |
$105 |
$49 |
$37 |
$1 |
|
$0.4 |
-$30.4 |
1.3 |
0.6 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
6/27/2003 Close |
% 52wk High |
% change from 6/28/2002 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value / Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| APPLIED MOLECULAR EVOLUTION |
$4.23 |
73% |
-27% |
$88 |
$58 |
$30 |
$10 |
106 |
$0.3 |
-$13.1 |
4.4 |
0.5 |
| ARENA PHARMACEUTICALS |
$6.76 |
81% |
-20% |
$193 |
$174 |
$19 |
$0 |
336 |
$0.1 |
-$35.2 |
4.9 |
0.6 |
| CELERA GENOMICS GROUP |
$10.51 |
73% |
-12% |
$757 |
na |
na |
na |
na |
na |
na |
na |
na |
| CURAGEN CORP |
$5.26 |
73% |
-7% |
$260 |
$395 |
-$135 |
$150 |
857 |
-$0.2 |
-$64.6 |
6.1 |
0.5 |
| DECODE GENETICS |
$3.19 |
64% |
-32% |
$171 |
$79 |
$91 |
$46 |
530 |
$0.2 |
-$52.2 |
1.5 |
0.4 |
| DELTAGEN |
$0.31 |
10% |
-87% |
$12 |
$3 |
$9 |
$3 |
268 |
$0.0 |
-$71.9 |
0.0 |
0.1 |
| EXELIXIS |
$7.12 |
73% |
-5% |
$498 |
$204 |
$294 |
$60 |
550 |
$0.5 |
-$92.2 |
2.2 |
1.1 |
| GENAISSANCE PHARMACEUTICALS |
$1.57 |
72% |
19% |
$36 |
$30 |
$6 |
$0 |
104 |
$0.1 |
-$18.9 |
1.6 |
0.2 |
| GENE LOGIC |
$5.91 |
42% |
-58% |
$184 |
$157 |
$26 |
$1 |
264 |
$0.1 |
-$23.2 |
6.8 |
0.5 |
| GENENCOR INTERNATIONAL |
$16.38 |
96% |
67% |
$960 |
$139 |
$821 |
$57 |
1098 |
$0.7 |
na |
na |
1.8 |
| LARGE SCALE BIOLOGY |
$1.04 |
46% |
-52% |
$27 |
$19 |
$7 |
$0 |
114 |
$0.1 |
-$30.5 |
0.6 |
0.1 |
| LEXICON GENETICS |
$6.55 |
94% |
59% |
$344 |
$108 |
$236 |
$4 |
579 |
$0.4 |
-$68.6 |
1.6 |
1.0 |
| LYNX THERAPEUTICS |
$3.73 |
42% |
-59% |
$17 |
$7 |
$10 |
$1 |
128 |
$0.1 |
-$15.9 |
0.5 |
0.2 |
| MAXYGEN |
$10.86 |
84% |
-11% |
$376 |
$198 |
$178 |
$0 |
280 |
$0.6 |
-$15.7 |
12.6 |
1.0 |
| NUVELO |
$1.83 |
64% |
-19% |
$115 |
$41 |
$74 |
$5 |
98 |
$0.8 |
-$54.3 |
0.8 |
0.6 |
| PARADIGM GENETICS |
$1.31 |
68% |
-6% |
$42 |
$11 |
$31 |
$2 |
194 |
$0.2 |
-$16.5 |
0.7 |
0.4 |
| RIGEL PHARMACEUTICALS |
$10.37 |
38% |
-68% |
$53 |
$22 |
$31 |
$0 |
160 |
$0.2 |
-$31.2 |
0.7 |
0.4 |
| SANGAMO BIOSCIENCES |
$2.76 |
43% |
-53% |
$68 |
$49 |
$19 |
$0 |
74 |
$0.3 |
-$11.6 |
4.2 |
0.5 |
| ZYMOGENETICS |
$11.82 |
66% |
34% |
$543 |
$268 |
$276 |
$0 |
364 |
$0.8 |
-$52.5 |
5.1 |
1.3 |
| Genomic Targets Average |
|
63% |
-18% |
$250 |
$109 |
$112 |
$19 |
|
$0.3 |
-$39.3 |
3.2 |
0.6 |
| Genomic Targets Median |
|
70% |
-16% |
$143 |
$58 |
$30 |
$1 |
|
$0.2 |
-$30.9 |
1.6 |
0.5 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
6/27/2003 Close |
% 52wk High |
% change from 6/28/2002 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value / Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| EDEN BIOSCIENCES |
$1.70 |
74% |
-15% |
$41 |
$26 |
$15 |
$0 |
55 |
$0.3 |
-$11.6 |
2.3 |
0.3 |
| EMBREX |
$9.77 |
45% |
-53% |
$80 |
$7 |
$73 |
$0 |
241 |
$0.3 |
na |
na |
1.3 |
| IDEXX LABORATORIES |
$34.16 |
87% |
32% |
$1,167 |
$175 |
$991 |
$0 |
1281 |
$0.8 |
na |
na |
3.3 |
| IMMUCELL CORP |
$2.69 |
90% |
-1% |
$7 |
$4 |
$3 |
$0 |
26 |
$0.1 |
na |
na |
0.8 |
| NEOGEN |
$16.50 |
94% |
21% |
$101 |
$8 |
$93 |
$0 |
265 |
$0.4 |
na |
na |
4.1 |
| Agbio/enviro. Average |
|
78% |
-3% |
$279 |
$44 |
$235 |
$0 |
|
$0.4 |
-$11.6 |
2.3 |
2.0 |
| Agbio/enviro. Median |
|
89% |
10% |
$61 |
$8 |
$44 |
$0 |
|
$0.3 |
-$5.3 |
1.6 |
1.1 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
6/27/2003 Close |
% 52wk High |
% change from 6/28/2002 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value / Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| ALEXION PHARMACEUTICALS |
$17.44 |
87% |
15% |
$318 |
$253 |
$64 |
$124 |
172 |
$0.4 |
-$85.9 |
2.9 |
0.8 |
| ATHEROGENICS |
$14.84 |
96% |
107% |
$541 |
$73 |
$468 |
$0 |
85 |
$5.5 |
-$46.0 |
1.6 |
3.2 |
| AUTOIMMUNE |
$1.53 |
68% |
139% |
$26 |
$11 |
$15 |
$0 |
2 |
$7.4 |
na |
na |
0.2 |
| CONNETICS CORP |
$15.02 |
82% |
16% |
$473 |
$29 |
$444 |
$0 |
190 |
$2.3 |
-$21.5 |
1.3 |
2.8 |
| CORTECH |
$2.81 |
83% |
-13% |
$10 |
$0 |
$10 |
$0 |
na |
na |
-$0.5 |
na |
na |
| CYPRESS BIOSCIENCE |
$4.21 |
74% |
116% |
$73 |
$10 |
$62 |
$0 |
10 |
$6.2 |
-$7.0 |
1.5 |
0.6 |
| ICOS CORP |
$37.62 |
82% |
122% |
$2,343 |
$156 |
$2,187 |
$0 |
525 |
$4.2 |
-$162.0 |
1.0 |
3.0 |
| INKINE PHARMACEUTICAL CO |
$3.33 |
92% |
292% |
$126 |
$11 |
$115 |
$12 |
49 |
$2.3 |
-$3.7 |
2.9 |
2.0 |
| LA JOLLA PHARMACEUTICAL CO |
$2.87 |
32% |
-54% |
$122 |
$39 |
$83 |
$1 |
156 |
$0.5 |
-$54.2 |
0.7 |
0.6 |
| PROTEIN DESIGN LABS |
$14.63 |
71% |
35% |
$1,366 |
$592 |
$773 |
$150 |
397 |
$1.9 |
na |
na |
2.2 |
| TANOX |
$16.00 |
80% |
48% |
$701 |
$207 |
$493 |
$5 |
127 |
$3.9 |
-$25.4 |
8.2 |
2.3 |
| Autoimmune Average |
|
77% |
75% |
$554 |
$126 |
$429 |
$27 |
|
$3.5 |
-$45.1 |
2.2 |
10.8 |
| Autoimmune Average |
|
82% |
74% |
$222 |
$34 |
$99 |
$1 |
|
$2.3 |
-$23.5 |
1.4 |
2.1 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
6/27/2003 Close |
% 52wk High |
% change from 6/28/2002 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value / Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| ALLOS THERAPEUTICS |
$2.82 |
29% |
-69% |
$73 |
$49 |
$24 |
$0 |
92 |
$0.3 |
-$28.4 |
1.7 |
0.4 |
| ANTIGENICS |
$12.32 |
77% |
25% |
$485 |
$103 |
$382 |
$0 |
212 |
$1.8 |
-$54.0 |
1.9 |
1.4 |
| APHTON CORP |
$7.35 |
88% |
-2% |
$182 |
$6 |
$176 |
$3 |
56 |
$3.1 |
-$19.7 |
0.3 |
1.4 |
| ARIAD PHARMACEUTICALS |
$3.88 |
80% |
-7% |
$135 |
$21 |
$114 |
$6 |
52 |
$2.2 |
-$21.2 |
1.0 |
0.9 |
| AVAX TECHNOLOGIES |
$0.27 |
45% |
-36% |
$4 |
$2 |
$3 |
$0 |
22 |
$0.1 |
-$4.4 |
0.4 |
0.1 |
| AVI BIOPHARMA |
$5.95 |
80% |
102% |
$185 |
$12 |
$174 |
$0 |
89 |
$2.0 |
-$13.7 |
0.9 |
1.3 |
| BIOMIRA |
$1.50 |
30% |
-46% |
$81 |
$83 |
-$2 |
$0 |
115 |
$0.0 |
-$17.6 |
4.7 |
0.9 |
| BOSTON LIFE SCIENCES |
$1.52 |
51% |
21% |
$49 |
$0 |
$49 |
$0 |
14 |
$3.5 |
na |
na |
na |
| BRITISH BIOTECH PLC |
$2.30 |
44% |
-50% |
$39 |
$284 |
-$245 |
$5 |
96 |
-$2.6 |
-$59.4 |
4.8 |
0.1 |
| CELGENE CORP |
$31.22 |
84% |
104% |
$2,522 |
$257 |
$2,265 |
$0 |
560 |
$4.0 |
na |
na |
4.2 |
| CELL THERAPEUTICS |
$9.93 |
63% |
82% |
$329 |
$110 |
$219 |
$86 |
286 |
$0.8 |
-$121.9 |
0.9 |
0.9 |
| CORIXA CORP |
$7.20 |
78% |
5% |
$363 |
$61 |
$301 |
$6 |
366 |
$0.8 |
-$74.8 |
0.8 |
0.3 |
| CYTOGEN CORP |
$7.57 |
66% |
-29% |
$67 |
$11 |
$56 |
$0 |
49 |
$1.1 |
-$7.8 |
1.4 |
0.2 |
| DENDREON |
$6.53 |
68% |
209% |
$175 |
$47 |
$128 |
$0 |
117 |
$1.1 |
-$30.8 |
1.5 |
1.1 |
| DUSA PHARMACEUTICALS |
$2.50 |
76% |
-14% |
$35 |
$48 |
-$13 |
$1 |
43 |
-$0.3 |
-$14.3 |
3.4 |
0.4 |
| ENTREMED |
$4.16 |
64% |
36% |
$119 |
$7 |
$112 |
$0 |
58 |
$1.9 |
-$14.8 |
0.4 |
0.5 |
| EXEGENICS |
$0.53 |
58% |
-35% |
$9 |
$15 |
-$7 |
$0 |
8 |
-$0.9 |
-$3.9 |
3.9 |
0.1 |
| GENAERA |
$1.85 |
71% |
4% |
$66 |
$8 |
$58 |
$0 |
22 |
$2.6 |
-$6.3 |
1.2 |
0.4 |
| GENTA |
$13.13 |
89% |
58% |
$971 |
$103 |
$867 |
$28 |
96 |
$9.0 |
-$38.4 |
2.7 |
3.0 |
| GERON CORP |
$7.13 |
73% |
56% |
$211 |
$40 |
$172 |
$16 |
92 |
$1.9 |
-$31.7 |
1.2 |
0.8 |
| ILEX ONCOLOGY |
$20.80 |
96% |
48% |
$680 |
$161 |
$519 |
$37 |
277 |
$1.9 |
-$99.7 |
1.6 |
1.5 |
| IMCLONE SYSTEMS |
$33.26 |
71% |
283% |
$2,461 |
$293 |
$2,168 |
$242 |
399 |
$5.4 |
-$168.0 |
1.7 |
7.1 |
| IMMUNOGEN |
$4.28 |
94% |
59% |
$174 |
$515 |
-$342 |
$0 |
1618 |
-$0.2 |
na |
na |
0.1 |
| IMMUNOMEDICS |
$6.25 |
74% |
20% |
$312 |
$28 |
$283 |
$0 |
94 |
$3.0 |
na |
na |
2.0 |
| MAXIM PHARMACEUTICALS |
$5.85 |
86% |
83% |
$136 |
$89 |
$48 |
$1 |
115 |
$0.4 |
-$43.9 |
2.0 |
0.4 |
| MEDAREX |
$6.52 |
72% |
-12% |
$504 |
$321 |
$182 |
$175 |
431 |
$0.4 |
-$118.5 |
2.7 |
0.8 |
| NAPRO BIOTHERAPEUTICS |
$1.68 |
25% |
-74% |
$50 |
$7 |
$44 |
$25 |
151 |
$0.3 |
-$11.0 |
0.6 |
0.5 |
| NEOPHARM |
$14.62 |
85% |
16% |
$239 |
$81 |
$159 |
$0 |
100 |
$1.6 |
-$45.1 |
1.8 |
1.4 |
| NEORX CORP |
$3.35 |
80% |
179% |
$90 |
$12 |
$78 |
$5 |
36 |
$2.2 |
-$16.5 |
0.7 |
0.4 |
| OSI PHARMACEUTICALS |
$32.71 |
88% |
35% |
$1,194 |
$354 |
$840 |
$160 |
429 |
$2.0 |
-$108.7 |
3.3 |
1.7 |
| OXIGENE |
$10.16 |
52% |
670% |
$128 |
$10 |
$118 |
$0 |
10 |
$11.8 |
-$5.9 |
1.7 |
1.5 |
| PRAECIS PHARMACEUTICALS |
$4.71 |
81% |
35% |
$244 |
$181 |
$63 |
$33 |
110 |
$0.6 |
-$45.7 |
4.0 |
0.7 |
| PROGENICS PHARMACEUTICALS |
$14.01 |
89% |
14% |
$179 |
$33 |
$146 |
$0 |
100 |
$1.5 |
-$24.4 |
1.4 |
1.9 |
| QLT INC |
$12.87 |
84% |
-4% |
$884 |
$126 |
$758 |
$0 |
336 |
$2.3 |
na |
na |
2.3 |
| SCICLONE PHARMACEUTICALS |
$8.73 |
96% |
337% |
$327 |
$18 |
$310 |
$6 |
97 |
$3.2 |
-$11.4 |
1.5 |
2.1 |
| SEATTLE GENETICS |
$4.93 |
83% |
-5% |
$152 |
$22 |
$130 |
$0 |
97 |
$1.3 |
-$23.8 |
0.9 |
1.4 |
| SPECTRUM PHARMACEUTICALS |
$4.72 |
73% |
-1% |
$15 |
na |
na |
$0 |
18 |
na |
-$6.8 |
na |
0.1 |
| SUPERGEN |
$5.32 |
73% |
-27% |
$174 |
$32 |
$143 |
$8 |
107 |
$1.3 |
-$46.7 |
0.7 |
0.6 |
| XENOVA GROUP PLC |
$2.02 |
20% |
-74% |
$35 |
$29 |
$6 |
$0 |
134 |
$0.0 |
-$13.9 |
2.1 |
1.2 |
| Cancer Average |
|
70% |
51% |
$361 |
$94 |
$276 |
$22 |
|
$1.9 |
-$39.8 |
1.8 |
1.2 |
| Cancer Average |
|
75% |
18% |
$174 |
$40 |
$128 |
$0 |
|
$1.5 |
-$23.8 |
1.5 |
0.9 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
6/27/2003 Close |
% 52wk High |
% change from 6/28/2002 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value / Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| CORVAS INTERNATIONAL |
$2.89 |
75% |
34% |
$80 |
$68 |
$12 |
$13 |
55 |
$0.2 |
-$18.5 |
3.7 |
0.4 |
| CV THERAPEUTICS |
$30.12 |
73% |
62% |
$852 |
$401 |
$450 |
$196 |
205 |
$2.2 |
-$82.9 |
4.8 |
1.5 |
| ENCYSIVE PHARMACEUTICALS |
$4.71 |
95% |
21% |
$209 |
$48 |
$161 |
$0 |
104 |
$1.5 |
-$18.6 |
2.6 |
1.0 |
| MEDICINES COMPANY |
$19.80 |
76% |
61% |
$927 |
$131 |
$796 |
$0 |
147 |
$5.4 |
-$25.7 |
5.1 |
2.1 |
| QUESTCOR PHARMACEUTICALS |
$0.98 |
68% |
-33% |
$38 |
$15 |
$23 |
$3 |
52 |
$0.4 |
-$7.1 |
2.1 |
0.4 |
| Cardiovascular Average |
|
77% |
29% |
$421 |
$132 |
$288 |
$42 |
|
$2.0 |
-$30.6 |
3.7 |
1.1 |
| Cardiovascular Median |
|
76% |
48% |
$144 |
$58 |
$92 |
$2 |
|
$1.3 |
-$18.6 |
3.1 |
1.0 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
6/27/2003 Close |
% 52wk High |
% change from 6/28/2002 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value / Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| ALBANY MOLECULAR RESEARCH |
$15.35 |
66% |
-27% |
$490 |
$124 |
$366 |
$66 |
860 |
$0.4 |
na |
na |
2.7 |
| ARGONAUT TECHNOLOGIES |
$1.30 |
74% |
14% |
$26 |
$23 |
$3 |
$12 |
215 |
$0.0 |
-$10.1 |
2.3 |
0.2 |
| ARQULE |
$3.95 |
53% |
-41% |
$92 |
$83 |
$10 |
$5 |
298 |
$0.0 |
-$3.0 |
27.6 |
0.4 |
| ARRAY BIOPHARMA |
$3.26 |
33% |
-66% |
$92 |
$41 |
$51 |
$0 |
245 |
$0.2 |
-$24.5 |
1.7 |
0.7 |
| BIOCRYST PHARMACEUTICALS |
$3.84 |
85% |
341% |
$68 |
$23 |
$45 |
$0 |
44 |
$1.0 |
-$11.2 |
2.0 |
0.5 |
| DISCOVERY PARTNERS |
$4.28 |
65% |
-35% |
$104 |
$71 |
$34 |
$0 |
236 |
$0.1 |
na |
na |
0.5 |
| KOSAN BIOSCIENCES |
$6.00 |
68% |
-31% |
$153 |
$53 |
$100 |
$0 |
112 |
$0.9 |
-$10.3 |
5.1 |
1.1 |
| PHARMACOPEIA |
$8.84 |
76% |
4% |
$209 |
$146 |
$63 |
$0 |
687 |
$0.1 |
-$21.8 |
6.7 |
0.7 |
| SYMYX TECHNOLOGIES |
$16.51 |
92% |
19% |
$513 |
$127 |
$386 |
$0 |
213 |
$1.8 |
na |
na |
3.3 |
| VERTEX PHARMACEUTICALS |
$15.38 |
64% |
-6% |
$1,180 |
$680 |
$500 |
$315 |
980 |
$0.5 |
na |
na |
1.5 |
| Chemistry Average |
|
68% |
17% |
$293 |
$137 |
$156 |
$40 |
|
$0.5 |
-$13.5 |
7.6 |
1.2 |
| Chemistry Median |
|
68% |
-6% |
$104 |
$71 |
$51 |
$0 |
|
$0.4 |
-$10.3 |
2.3 |
0.7 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
6/27/2003 Close |
% 52wk High |
% change from 6/28/2002 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value / Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| ADOLOR |
$12.19 |
76% |
8% |
$385 |
$137 |
$248 |
$0 |
124 |
$2.0 |
-$45.3 |
3.0 |
1.5 |
| CEPHALON |
$41.28 |
70% |
-9% |
$2,291 |
$547 |
$1,744 |
$860 |
1271 |
$1.4 |
na |
na |
2.2 |
| DOV PHARMACEUTICALS |
$10.98 |
92% |
na |
$160 |
$57 |
$102 |
$14 |
32 |
$3.2 |
-$10.4 |
5.5 |
1.9 |
| GUILFORD PHARMACEUTICALS |
$4.42 |
60% |
-41% |
$132 |
$66 |
$66 |
$4 |
235 |
$0.3 |
-$44.8 |
1.5 |
0.4 |
| INDEVUS PHARMACEUTICALS |
$6.40 |
45% |
452% |
$356 |
$33 |
$323 |
$0 |
24 |
$13.5 |
-$48.0 |
0.7 |
1.2 |
| NEUROBIOLOGICAL TECHNOLOGIES |
$3.71 |
42% |
29% |
$67 |
$5 |
$63 |
$0 |
11 |
$5.7 |
-$3.0 |
1.5 |
1.5 |
| NEUROCRINE BIOSCIENCES |
$51.25 |
85% |
79% |
$1,603 |
$308 |
$1,294 |
$0 |
276 |
$4.7 |
-$53.6 |
5.8 |
3.7 |
| NYMOX PHARMACEUTICAL |
$3.22 |
56% |
-31% |
$76 |
$0 |
$76 |
na |
228 |
$0.3 |
na |
na |
na |
| PAIN THERAPEUTICS |
$5.88 |
59% |
-30% |
$160 |
$46 |
$114 |
$0 |
30 |
$3.8 |
-$18.5 |
2.5 |
1.5 |
| PHARMOS CORP |
$2.01 |
76% |
118% |
$124 |
$17 |
$107 |
$0 |
67 |
$1.6 |
-$18.0 |
0.9 |
1.0 |
| STEMCELLS |
$1.60 |
56% |
-1% |
$47 |
$2 |
$46 |
$0 |
28 |
$1.6 |
-$9.6 |
0.2 |
0.3 |
| TITAN PHARMACEUTICALS |
$2.10 |
50% |
-37% |
$58 |
$66 |
-$8 |
$0 |
72 |
-$0.1 |
-$26.1 |
2.5 |
0.3 |
| CNS Average |
|
64% |
49% |
$455 |
$107 |
$348 |
$80 |
|
$3.2 |
-$27.7 |
2.4 |
1.4 |
| CNS Median |
|
60% |
4% |
$132 |
$46 |
$102 |
$0 |
|
$1.6 |
-$18.5 |
1.5 |
1.3 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
6/27/2003 Close |
% 52wk High |
% change from 6/28/2002 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value / Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| BIOSOURCE INTERNATIONAL |
$6.88 |
98% |
17% |
$66 |
$4 |
$62 |
$0 |
296 |
$0.2 |
na |
na |
1.5 |
| GTC BIOTHERAPEUTICS |
$3.18 |
73% |
152% |
$89 |
$48 |
$41 |
$13 |
182 |
$0.2 |
-$29.6 |
1.6 |
0.4 |
| HARVARD BIOSCIENCE |
$3.80 |
56% |
-32% |
$114 |
$9 |
$105 |
$0 |
386 |
$0.3 |
na |
na |
0.7 |
| ICON PLC |
$30.74 |
94% |
8% |
$363 |
na |
na |
na |
1637 |
na |
na |
na |
na |
| INVITROGEN CORP |
$39.22 |
93% |
23% |
$1,963 |
$764 |
$1,199 |
$697 |
2744 |
$0.4 |
na |
na |
1.0 |
| MOLECULAR DEVICES CORP |
$14.62 |
75% |
-18% |
$224 |
$55 |
$168 |
$0 |
433 |
$0.4 |
na |
na |
1.2 |
| NEOSE TECHNOLOGIES |
$10.05 |
72% |
-8% |
$173 |
$52 |
$121 |
$8 |
124 |
$1.0 |
-$33.7 |
1.5 |
0.9 |
| PARAXEL INTERNATIONAL |
$13.95 |
94% |
0% |
$358 |
$76 |
$282 |
$1 |
4930 |
$0.1 |
na |
na |
2.1 |
| PHARMACEUTICAL PRODUCT DEVELOP |
$29.07 |
90% |
10% |
$1,620 |
$186 |
$1,434 |
$6 |
5300 |
$0.3 |
na |
na |
5.9 |
| QIAGEN NV |
$8.27 |
74% |
-29% |
$1,204 |
$30 |
$1,174 |
$0 |
1651 |
$0.7 |
na |
na |
24.3 |
| QUINTILES TRANSNATIONAL CORP |
$14.21 |
100% |
14% |
$1,681 |
$731 |
$949 |
$0 |
15548 |
$0.1 |
na |
na |
1.9 |
| CRO/Service/Supply Average |
|
83% |
12% |
$714 |
$196 |
$554 |
$73 |
|
$0.4 |
-$31.6 |
1.6 |
4.0 |
| CRO/Service/Supply Median |
|
92% |
9% |
$291 |
$52 |
$168 |
$1 |
|
$0.3 |
-$29.6 |
1.5 |
1.2 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
6/27/2003 Close |
% 52wk High |
% change from 6/28/2002 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value / Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| ABGENIX |
$10.99 |
75% |
12% |
$966 |
$346 |
$620 |
$200 |
387 |
$1.6 |
-$132.7 |
2.6 |
1.0 |
| AEROGEN |
$0.53 |
48% |
-40% |
$11 |
$4 |
$6 |
$0 |
80 |
$0.1 |
-$17.2 |
0.3 |
0.1 |
| ALKERMES |
$11.06 |
76% |
-31% |
$713 |
$158 |
$556 |
$172 |
520 |
$1.1 |
na |
na |
1.5 |
| ANDRX |
$19.81 |
71% |
-27% |
$1,424 |
$67 |
$1,357 |
$0 |
2100 |
$0.6 |
na |
na |
2.9 |
| ARADIGM CORP |
$1.82 |
41% |
-58% |
$92 |
$36 |
$56 |
$0 |
285 |
$0.2 |
-$31.7 |
1.1 |
0.3 |
| ATRIX LABORATORIES |
$22.07 |
95% |
-1% |
$453 |
$96 |
$358 |
$0 |
167 |
$2.1 |
-$11.0 |
8.7 |
1.8 |
| BIODELIVERY SCIENCES |
$4.00 |
89% |
na |
$28 |
$6 |
$23 |
$0 |
19 |
$1.2 |
-$2.3 |
2.5 |
2.0 |
| CIMA LABS |
$27.59 |
90% |
14% |
$395 |
$72 |
$323 |
$0 |
219 |
$1.5 |
na |
na |
1.6 |
| DEPOMED |
$4.99 |
93% |
61% |
$128 |
$13 |
$115 |
$0 |
51 |
$2.3 |
-$25.2 |
0.5 |
1.9 |
| DOR BIOPHARMA |
$0.90 |
53% |
210% |
$25 |
$3 |
$21 |
$0 |
5 |
$4.3 |
-$9.7 |
0.3 |
0.3 |
| DURECT |
$2.39 |
31% |
-70% |
$121 |
$37 |
$84 |
$0 |
6 |
$13.9 |
-$23.6 |
1.6 |
0.6 |
| EMISPHERE TECHNOLOGIES |
$3.67 |
58% |
-12% |
$66 |
$53 |
$13 |
$34 |
124 |
$0.1 |
-$39.5 |
1.3 |
0.2 |
| ENZON PHARMACEUTICALS |
$13.01 |
51% |
-48% |
$565 |
$100 |
$466 |
$0 |
127 |
$3.7 |
na |
na |
2.1 |
| FLAMEL TECHNOLOGIES SA |
$13.95 |
99% |
806% |
$226 |
$13 |
$213 |
$2 |
150 |
$1.4 |
-$8.9 |
1.5 |
4.4 |
| GENEREX BIOTECHNOLOGY |
$1.70 |
53% |
-42% |
$34 |
$12 |
$23 |
$2 |
23 |
$1.0 |
-$10.4 |
1.1 |
0.4 |
| GENETRONICS BIOMEDICAL LTD |
$0.74 |
78% |
57% |
$37 |
$2 |
$35 |
$0 |
26 |
$1.4 |
na |
na |
0.7 |
| KOS PHARMACEUTICALS |
$23.33 |
86% |
15% |
$489 |
$26 |
$463 |
$0 |
726 |
$0.6 |
na |
na |
2.2 |
| MACROCHEM CORP |
$1.07 |
59% |
-39% |
$30 |
$8 |
$23 |
$0 |
13 |
$1.8 |
-$4.7 |
1.6 |
0.4 |
| MEDICIS PHARMACEUTICAL |
$56.15 |
91% |
31% |
$1,525 |
$539 |
$986 |
$400 |
279 |
$3.5 |
na |
na |
3.5 |
| NASTECH PHARMACEUTICAL |
$10.27 |
63% |
-37% |
$105 |
$17 |
$88 |
$4 |
63 |
$1.4 |
-$11.7 |
1.4 |
1.7 |
| NEKTAR THERAPEUTICS |
$9.05 |
63% |
-5% |
$504 |
$252 |
$253 |
$299 |
680 |
$0.4 |
-$79.8 |
3.2 |
0.7 |
| NOVAVAX |
$5.50 |
80% |
31% |
$163 |
$14 |
$149 |
$41 |
121 |
$1.2 |
-$23.2 |
0.6 |
1.4 |
| NOVEN PHARMACEUTICALS |
$10.30 |
41% |
-60% |
$232 |
$65 |
$166 |
$0 |
274 |
$0.6 |
na |
na |
3.0 |
| SEPRACOR |
$18.40 |
63% |
93% |
$1,552 |
$482 |
$1,071 |
$983 |
818 |
$1.3 |
-$119.0 |
4.0 |
2.0 |
| Delivery Average |
|
69% |
37% |
$412 |
$101 |
$311 |
$89 |
|
$2.0 |
-$34.4 |
2.0 |
1.5 |
| Delivery Median |
|
71% |
-3% |
$163 |
$36 |
$149 |
$0 |
|
$1.3 |
-$17.2 |
1.4 |
1.5 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
6/27/2003 Close |
% 52wk High |
% change from 6/28/2002 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value / Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| ADVANCED MAGNETICS |
$10.32 |
84% |
174% |
$69 |
$15 |
$53 |
$0 |
23 |
$2.3 |
-$2.6 |
6.0 |
1.6 |
| BIOSITE |
$48.96 |
90% |
74% |
$734 |
$72 |
$662 |
$7 |
513 |
$1.3 |
na |
na |
9.1 |
| CHOLESTECH CORP |
$10.18 |
67% |
-4% |
$140 |
$16 |
$124 |
$0 |
220 |
$0.6 |
-$14.8 |
1.1 |
1.7 |
| DIAGNOSTIC PRODUCTS CORP |
$41.73 |
88% |
13% |
$1,196 |
$33 |
$1,162 |
$0 |
2100 |
$0.6 |
na |
na |
19.5 |
| DIGENE CORP |
$28.01 |
98% |
138% |
$508 |
$31 |
$477 |
$3 |
243 |
$2.0 |
-$2.5 |
12.5 |
4.4 |
| ENZO BIOCHEM |
$22.12 |
77% |
54% |
$630 |
$79 |
$551 |
$0 |
231 |
$2.4 |
na |
na |
3.9 |
| EPIX MEDICAL |
$13.81 |
96% |
31% |
$237 |
$21 |
$216 |
$0 |
93 |
$2.3 |
-$21.8 |
1.0 |
2.0 |
| EXACT SCIENCES |
$10.99 |
69% |
-31% |
$209 |
$35 |
$174 |
$0 |
75 |
$2.3 |
-$31.5 |
1.1 |
1.8 |
| GEN-PROBE |
$41.50 |
95% |
na |
$988 |
$0 |
$988 |
$0 |
186 |
$5.3 |
na |
na |
na |
| HYCOR BIOMEDICAL |
$4.85 |
96% |
34% |
$39 |
$5 |
$34 |
$0 |
148 |
$0.2 |
na |
na |
3.0 |
| IGEN INTERNATIONAL |
$31.60 |
69% |
0% |
$751 |
$42 |
$709 |
$45 |
370 |
$1.9 |
-$17.2 |
2.4 |
3.1 |
| IMMUCOR |
$21.70 |
84% |
39% |
$277 |
$5 |
$272 |
$20 |
481 |
$0.6 |
na |
na |
9.1 |
| LUMINEX |
$5.27 |
65% |
-30% |
$156 |
$39 |
$117 |
$0 |
117 |
$1.0 |
-$3.6 |
10.9 |
1.3 |
| MARTEK BIOSCIENCES CORP |
$43.56 |
89% |
108% |
$1,170 |
$103 |
$1,067 |
$0 |
198 |
$5.4 |
na |
na |
3.6 |
| MATRITECH |
$2.36 |
79% |
-7% |
$76 |
$7 |
$69 |
$4 |
50 |
$1.4 |
-$7.8 |
0.9 |
1.0 |
| MERIDIAN BIOSCIENCE |
$9.18 |
87% |
39% |
$135 |
$3 |
$131 |
$23 |
350 |
$0.4 |
na |
na |
5.7 |
| ORASURE |
$7.77 |
90% |
20% |
$298 |
$15 |
$283 |
$3 |
187 |
$1.5 |
-$4.4 |
3.5 |
1.9 |
| OSTEX INTERNATIONAL |
$2.15 |
81% |
57% |
$27 |
$1 |
$26 |
$0 |
48 |
$0.5 |
-$2.6 |
0.5 |
0.6 |
| QUIDEL CORP |
$5.90 |
87% |
-14% |
$171 |
$13 |
$157 |
$10 |
330 |
$0.5 |
na |
na |
1.2 |
| SONUS PHARMACEUTICALS |
$3.78 |
88% |
81% |
$52 |
$14 |
$38 |
$0 |
37 |
$1.0 |
-$9.1 |
1.5 |
0.9 |
| TRINITY BIOTECH PLC |
$3.03 |
87% |
116% |
$123 |
$1 |
$121 |
$0 |
332 |
$0.4 |
na |
na |
5.7 |
| Diagnostic/imag. Average |
|
84% |
45% |
$380 |
$26 |
$354 |
$5 |
|
$1.6 |
-$10.7 |
3.8 |
4.0 |
| Diagnostic/imag. Median |
|
87% |
39% |
$190 |
$15 |
$166 |
$0 |
|
$1.2 |
-$6.1 |
1.3 |
2.0 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
6/27/2003 Close |
% 52wk High |
% change from 6/28/2002 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value / Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| AASTROM BIOSCIENCES |
$1.06 |
61% |
186% |
$60 |
$5 |
$55 |
$0 |
44 |
$1.3 |
-$8.4 |
0.6 |
0.6 |
| AVIGEN |
$3.52 |
34% |
-63% |
$71 |
$105 |
-$34 |
$8 |
102 |
-$0.3 |
-$23.9 |
4.4 |
0.3 |
| CELL GENESYS |
$9.20 |
62% |
-33% |
$342 |
$161 |
$180 |
$60 |
336 |
$0.5 |
-$69.5 |
2.3 |
1.2 |
| CORAUTUS GENETICS |
$3.05 |
51% |
21% |
$30 |
$3 |
$28 |
$0 |
17 |
$1.6 |
-$85.8 |
0.0 |
0.4 |
| DIACRIN |
$2.75 |
58% |
95% |
$49 |
$41 |
$9 |
$0 |
29 |
$0.3 |
-$5.5 |
7.4 |
0.5 |
| GENVEC |
$2.00 |
45% |
-9% |
$45 |
$12 |
$33 |
$6 |
95 |
$0.4 |
-$20.6 |
0.6 |
0.4 |
| INTROGEN |
$5.58 |
55% |
175% |
$120 |
$19 |
$101 |
$7 |
50 |
$2.0 |
-$21.8 |
0.9 |
1.3 |
| SIRNA THERAPEUTICS |
$8.74 |
76% |
6% |
$247 |
$5 |
$242 |
$4 |
81 |
$3.0 |
-$19.7 |
0.2 |
1.2 |
| TARGETED GENETICS CORP |
$1.91 |
43% |
77% |
$97 |
$12 |
$84 |
$0 |
125 |
$0.7 |
-$3.3 |
3.7 |
0.4 |
| TRANSGENE SA |
$2.39 |
51% |
33% |
$72 |
na |
na |
$0 |
318 |
na |
na |
na |
na |
| TRANSKARYOTIC THERAPIES |
$11.00 |
26% |
-69% |
$384 |
$212 |
$172 |
$0 |
345 |
$0.5 |
-$103.8 |
2.0 |
0.6 |
| VALENTIS |
$3.19 |
98% |
-92% |
$18 |
$6 |
$12 |
$0 |
58 |
$0.2 |
-$12.1 |
0.5 |
0.1 |
| VICAL |
$4.28 |
59% |
-19% |
$86 |
$102 |
-$16 |
$0 |
165 |
-$0.1 |
-$28.1 |
3.6 |
0.4 |
| Gene therapy Average |
|
55% |
24% |
$125 |
$57 |
$72 |
$7 |
|
$0.8 |
-$33.5 |
2.2 |
0.6 |
| Gene therapy Median |
|
56% |
13% |
$71 |
$12 |
$33 |
$0 |
|
$0.5 |
-$20.6 |
1.0 |
0.5 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
6/27/2003 Close |
% 52wk High |
% change from 6/28/2002 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value / Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| AVANT IMMUNOTHERAPEUTICS |
$2.62 |
76% |
134% |
$158 |
$20 |
$138 |
$0 |
66 |
$2.1 |
-$13.4 |
1.5 |
0.7 |
| CUBIST PHARMACEUTICALS |
$10.57 |
78% |
12% |
$312 |
$114 |
$198 |
$208 |
204 |
$1.0 |
-$100.0 |
1.1 |
1.2 |
| EPIMMUNE |
$1.32 |
63% |
-22% |
$16 |
$8 |
$9 |
$0 |
52 |
$0.2 |
-$7.2 |
1.0 |
0.1 |
| GENELABS TECHNOLOGIES |
$1.56 |
44% |
-22% |
$96 |
$2 |
$94 |
$0 |
94 |
$1.0 |
-$16.8 |
0.1 |
0.5 |
| IMMUNE RESPONSE CORP |
$3.25 |
82% |
132% |
$64 |
$2 |
$62 |
$5 |
43 |
$1.4 |
-$20.8 |
0.1 |
0.3 |
| INTERMUNE |
$15.17 |
40% |
-28% |
$482 |
$277 |
$205 |
$150 |
250 |
$0.8 |
-$75.7 |
3.7 |
1.0 |
| INTRABIOTICS |
$4.37 |
15% |
-72% |
$14 |
$11 |
$3 |
$0 |
8 |
$0.4 |
-$7.6 |
1.5 |
0.1 |
| MEDIMMUNE |
$35.84 |
85% |
36% |
$9,035 |
$568 |
$8,467 |
$217 |
1505 |
$5.6 |
na |
na |
3.4 |
| NABI BIOPHARMACEUTICALS |
$6.80 |
85% |
44% |
$266 |
$47 |
$219 |
$0 |
722 |
$0.3 |
na |
na |
1.6 |
| SIGA TECHNOLOGIES |
$1.63 |
68% |
46% |
$22 |
$2 |
$20 |
$0 |
17 |
$1.2 |
-$121.5 |
0.0 |
0.7 |
| TRIMERIS |
$46.77 |
82% |
5% |
$1,000 |
$140 |
$860 |
$0 |
129 |
$6.7 |
-$63.7 |
2.2 |
2.5 |
| VAXGEN |
$5.11 |
22% |
-8% |
$81 |
$10 |
$71 |
$0 |
117 |
$0.6 |
-$26.6 |
0.4 |
0.5 |
| VICURON |
$14.20 |
91% |
6% |
$376 |
$145 |
$230 |
$0 |
28 |
$8.2 |
-$48.0 |
3.0 |
0.9 |
| VION PHARMACEUTICALS |
$1.62 |
54% |
315% |
$47 |
$8 |
$39 |
$0 |
34 |
$1.1 |
-$9.7 |
0.8 |
0.4 |
| VIROLOGIC |
$1.31 |
45% |
-53% |
$38 |
$10 |
$28 |
$0 |
170 |
$0.2 |
-$9.9 |
1.0 |
0.3 |
| VIROPHARMA |
$2.66 |
56% |
86% |
$69 |
$145 |
-$76 |
$130 |
139 |
-$0.5 |
-$27.4 |
5.3 |
0.3 |
| XOMA LTD |
$5.76 |
72% |
44% |
$415 |
$33 |
$382 |
$71 |
229 |
$1.7 |
-$52.4 |
0.6 |
0.8 |
| Infection Average |
|
62% |
39% |
$735 |
$91 |
$644 |
$46 |
|
$1.9 |
-$40.0 |
1.5 |
0.9 |
| Infection Median |
|
70% |
24% |
$89 |
$16 |
$83 |
$0 |
|
$1.0 |
-$23.7 |
1.0 |
0.7 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
6/27/2003 Close |
% 52wk High |
% change from 6/28/2002 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value / Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| AMYLIN PHARMACEUTICALS |
$22.31 |
83% |
104% |
$2,070 |
$264 |
$1,805 |
$0 |
350 |
$5.2 |
-$123.2 |
2.1 |
3.0 |
| BIOMARIN PHARMACEUTICAL |
$9.44 |
69% |
81% |
$598 |
$154 |
$445 |
$0 |
219 |
$2.0 |
-$78.7 |
2.0 |
1.5 |
| INSMED INC |
$2.72 |
76% |
94% |
$90 |
$0 |
$90 |
$0 |
23 |
$3.9 |
na |
na |
na |
| KERYX BIOPHARMACEUTICALS |
$2.17 |
76% |
-4% |
$44 |
$22 |
$22 |
$0 |
24 |
$0.9 |
-$15.2 |
1.5 |
0.6 |
| NPS PHARMACEUTICALS |
$25.00 |
81% |
63% |
$880 |
$209 |
$671 |
$0 |
183 |
$3.7 |
-$112.4 |
1.9 |
1.8 |
| SAVIENT PHARMACEUTICALS |
$4.38 |
72% |
-27% |
$259 |
$23 |
$236 |
$11 |
490 |
$0.5 |
na |
na |
1.2 |
| VIVUS |
$5.38 |
81% |
-21% |
$179 |
$23 |
$156 |
$0 |
119 |
$1.3 |
-$12.8 |
1.8 |
1.3 |
| ZONAGEN |
$1.64 |
95% |
9% |
$19 |
$24 |
-$6 |
$0 |
4 |
-$1.4 |
-$3.8 |
6.5 |
0.2 |
| Metabolic Average |
|
79% |
37% |
$517 |
$90 |
$427 |
$1 |
|
$2.0 |
-$57.7 |
2.6 |
1.4 |
| Metabolic Median |
|
81% |
63% |
$179 |
$23 |
$156 |
$0 |
|
$1.3 |
-$15.2 |
1.9 |
1.3 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
6/27/2003 Close |
% 52wk High |
% change from 6/28/2002 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value / Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| BIOPURE CORP |
$6.00 |
72% |
-22% |
$236 |
$15 |
$221 |
$10 |
249 |
$0.9 |
-$46.6 |
0.3 |
0.5 |
| BIORELIANCE CORP |
$22.93 |
82% |
-8% |
$195 |
$36 |
$160 |
$10 |
638 |
$0.3 |
na |
na |
3.5 |
| BIOTIME |
$1.99 |
67% |
-7% |
$27 |
$1 |
$26 |
$2 |
12 |
$2.2 |
-$3.0 |
0.2 |
0.8 |
| CERUS |
$7.70 |
23% |
-77% |
$169 |
$96 |
$73 |
$51 |
158 |
$0.5 |
-$68.6 |
1.4 |
4.3 |
| COLLAGENEX PHARMACEUTICALS |
$13.13 |
97% |
77% |
$150 |
$10 |
$140 |
$0 |
148 |
$0.9 |
na |
na |
1.8 |
| COLUMBIA LABORATORIES |
$11.31 |
98% |
89% |
$401 |
$4 |
$397 |
$10 |
25 |
$15.9 |
-$18.8 |
0.2 |
3.2 |
| CURIS |
$3.60 |
64% |
195% |
$114 |
$37 |
$78 |
$7 |
64 |
$1.2 |
-$17.2 |
2.1 |
0.2 |
| CYANOTECH CORP |
$0.50 |
59% |
-21% |
$9 |
$1 |
$9 |
$4 |
58 |
$0.1 |
-$0.7 |
0.9 |
0.4 |
| CYTRX CORP |
$1.95 |
52% |
225% |
$45 |
$1 |
$44 |
$0 |
3 |
$14.7 |
-$3.7 |
0.4 |
0.6 |
| DISCOVERY LABORATORIES |
$6.09 |
82% |
248% |
$200 |
$14 |
$186 |
$0 |
65 |
$2.9 |
-$18.0 |
0.8 |
2.3 |
| INSITE VISION |
$0.65 |
38% |
-55% |
$16 |
$1 |
$15 |
$0 |
41 |
$0.4 |
-$9.1 |
0.1 |
0.1 |
| INSPIRE PHARMACEUTICALS |
$11.03 |
67% |
186% |
$350 |
$96 |
$254 |
$0 |
54 |
$4.7 |
na |
na |
1.8 |
| INTEGRA LIFESCIENCES |
$27.25 |
91% |
25% |
$710 |
$129 |
$581 |
$105 |
760 |
$0.8 |
na |
na |
2.4 |
| NORTHFIELD LABORATORIES |
$8.10 |
81% |
102% |
$116 |
$9 |
$106 |
$0 |
60 |
$1.8 |
-$11.6 |
0.8 |
1.0 |
| OSTEOTECH |
$13.67 |
94% |
85% |
$233 |
$15 |
$218 |
$15 |
338 |
$0.6 |
na |
na |
3.7 |
| PALATIN TECHNOLOGIES |
$3.14 |
75% |
59% |
$131 |
$26 |
$106 |
$0 |
46 |
$2.3 |
-$22.6 |
1.1 |
1.2 |
| PHARMACYCLICS |
$4.75 |
83% |
7% |
$77 |
$94 |
-$17 |
$0 |
133 |
-$0.1 |
-$28.8 |
3.3 |
0.3 |
| REPLIGEN CORP |
$5.03 |
72% |
123% |
$138 |
$18 |
$120 |
$0 |
39 |
$3.1 |
-$3.1 |
5.7 |
0.8 |
| SALIX PHARMACEUTICALS |
$10.78 |
71% |
-29% |
$231 |
$40 |
$191 |
$0 |
135 |
$1.4 |
-$21.9 |
1.8 |
1.8 |
| SANGSTAT MEDICAL CORP |
$13.43 |
53% |
-42% |
$355 |
$95 |
$261 |
$5 |
299 |
$0.9 |
na |
na |
1.1 |
| TRIPOS |
$7.18 |
49% |
-67% |
$64 |
$10 |
$54 |
$4 |
337 |
$0.2 |
na |
na |
1.8 |
| Other Average |
|
70% |
52% |
$189 |
$36 |
$153 |
$11 |
|
$2.6 |
-$19.5 |
1.4 |
1.6 |
| Other Median |
|
72% |
42% |
$144 |
$15 |
$113 |
$2 |
|
$1.0 |
-$17.2 |
0.9 |
1.2 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
6/27/2003 Close |
% 52wk High |
% change from 6/28/2002 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value / Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| AMGEN |
$65.18 |
97% |
56% |
$84,082 |
$4,757 |
$79,325 |
$3,056 |
10100 |
$7.9 |
na |
na |
4.3 |
| BIOGEN |
$39.53 |
78% |
-5% |
$5,869 |
$812 |
$5,056 |
$37 |
2633 |
$1.9 |
na |
na |
7.0 |
| CHIRON CORP |
$44.04 |
90% |
25% |
$8,210 |
$843 |
$7,367 |
$419 |
4044 |
$1.8 |
na |
na |
3.3 |
| GENENTECH |
$73.60 |
95% |
120% |
$37,547 |
$1,085 |
$36,462 |
$0 |
5252 |
$6.9 |
na |
na |
5.7 |
| GENZYME CORP |
$42.99 |
86% |
123% |
$9,277 |
$515 |
$8,762 |
$600 |
5600 |
$1.6 |
na |
na |
3.3 |
| GILEAD SCIENCES |
$56.31 |
98% |
71% |
$11,264 |
$612 |
$10,652 |
$595 |
1250 |
$8.5 |
na |
na |
11.1 |
| IDEC PHARMACEUTICALS CORP |
$35.29 |
74% |
0% |
$5,473 |
$860 |
$4,613 |
$871 |
995 |
$4.6 |
na |
na |
5.5 |
| Revenue-driven Average |
|
88% |
56% |
$23,103 |
$1,355 |
$21,748 |
$797 |
|
$4.8 |
na |
na |
5.8 |
| Revenue-driven Median |
|
92% |
63% |
$8,743 |
$828 |
$8,064 |
$507 |
|
$3.3 |
na |
na |
4.9 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
6/27/2003 Close |
% 52wk High |
% change from 6/28/2002 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value / Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| DIVERSA |
$9.68 |
81% |
-3% |
$406 |
$155 |
$251 |
$11 |
279 |
$0.9 |
-$83.9 |
1.8 |
1.2 |
| DYAX |
$4.00 |
82% |
3% |
$98 |
$31 |
$67 |
$18 |
244 |
$0.3 |
-$25.5 |
1.2 |
0.7 |
| ISIS PHARMACEUTICALS |
$5.40 |
46% |
-43% |
$299 |
$269 |
$30 |
$200 |
523 |
$0.1 |
-$97.3 |
2.8 |
0.5 |
| LIGAND PHARMACEUTICALS |
$13.50 |
81% |
-7% |
$935 |
$34 |
$901 |
$159 |
402 |
$2.2 |
-$81.3 |
0.4 |
1.4 |
| NEUROGEN CORP |
$4.88 |
40% |
-58% |
$87 |
$71 |
$16 |
$14 |
163 |
$0.1 |
-$31.6 |
2.3 |
0.5 |
| ONYX PHARMACEUTICALS |
$11.54 |
77% |
100% |
$275 |
$38 |
$237 |
$0 |
89 |
$2.7 |
-$42.8 |
0.9 |
1.4 |
| REGENERON PHARMACEUTICALS |
$16.42 |
72% |
13% |
$770 |
$312 |
$458 |
$200 |
266 |
$1.7 |
-$120.4 |
2.6 |
1.2 |
| TULARIK |
$9.57 |
80% |
4% |
$529 |
$156 |
$373 |
$0 |
430 |
$0.9 |
-$96.8 |
1.6 |
1.3 |
| Screening Average |
|
70% |
1% |
$425 |
$133 |
$292 |
$75 |
|
$1.1 |
-$72.5 |
1.7 |
1.0 |
| Screening Median |
|
80% |
3% |
$299 |
$71 |
$237 |
$14 |
|
$0.9 |
-$81.3 |
1.6 |
1.2 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
6/27/2003 Close |
% 52wk High |
% change from 6/28/2002 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value / Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| CARRINGTON LABORATORIES |
$2.65 |
92% |
121% |
$27 |
$2 |
$24 |
$2 |
252 |
$0.1 |
-$1.2 |
2.0 |
0.5 |
| CELLEGY PHARMACEUTICALS |
$5.02 |
82% |
128% |
$100 |
$12 |
$88 |
$0 |
23 |
$3.8 |
-$12.5 |
0.9 |
1.0 |
| CURATIVE HEALTH SERVICES |
$16.55 |
84% |
-1% |
$204 |
$2 |
$202 |
$24 |
340 |
$0.6 |
na |
na |
1.9 |
| LIFECELL CORP |
$5.24 |
84% |
114% |
$112 |
$5 |
$106 |
$1 |
155 |
$0.7 |
na |
na |
1.4 |
| LIFECORE BIOMEDICAL |
$5.67 |
51% |
-50% |
$73 |
$3 |
$70 |
$6 |
199 |
$0.4 |
na |
na |
1.5 |
| Wound Average |
|
79% |
62% |
$103 |
$5 |
$98 |
$7 |
|
$1.1 |
-$6.9 |
1.4 |
1.3 |
| Wound Median |
|
84% |
107% |
$86 |
$3 |
$79 |
$1 |
|
$0.6 |
-$1.2 |
1.0 |
1.2 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Grand Average |
|
71% |
33% |
$1,002 |
$135 |
$888 |
$56 |
|
$1.7 |
-$38.4 |
2.4 |
2.0 |
| Grand Median |
|
74% |
12% |
$174 |
$41 |
$128 |
$1 |
|
$0.9 |
-$23.6 |
1.6 |
1.2 |
originally published 07/03/2003 |